ALUVI.PA • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALUVI.PA in your mock portfolio yet.
With EPS of €0.18 and a PE ratio of 16.56, UV Germi SA appears modestly profitable and roughly fairly valued relative to typical small-cap industrial/clean-tech peers. The valuation does not suggest extreme optimism or distress, but without multi-period revenue and margin data, it is difficult to argue for a strong growth or deep value case. Overall, the financial profile looks stable but not clearly high-growth.
The stock trades at €2.98, essentially flat over the last month, suggesting a consolidation phase rather than a strong trend. Price is above the 200-day moving average of €2.63 and the RSI at 63.60 is in the upper neutral zone, indicating mild upward momentum but not yet overbought. Overall, technicals lean slightly positive but not convincingly enough to call a strong bullish trend.
Alternative data suggest limited external growth momentum or brand traction. Website traffic is very low at an estimated 429 visitors per month, job openings are at zero, and social media followings are small with minimal growth across platforms. These signals collectively point to subdued commercial and marketing activity, which may cap near-term growth expectations.
UV Germi SA shows a modestly profitable profile with a mid-teens PE and positive EPS, and its stock trades above the 200-day moving average with a mildly constructive RSI, supporting a neutral-to-slightly-positive technical stance. However, very weak alternative data signals—low web traffic, no hiring, and stagnant social media growth—temper the outlook and suggest limited near-term growth catalysts. Overall, the balance of fundamentals, valuation, and alternative data supports a neutral view on the stock at current levels.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: